Dr. Joseph Mikhael

Dr Mikhael is a Professor at the Applied Cancer Research and Drug Discovery Division at the Translational Genomics Research Institute (TGen), an affiliate of City of Hope National Medical Center located in Phoenix, Arizona; he is also Director of Myeloma Research at Honour Health and Chief Medical Officer at the International Myeloma Foundation, the largest myeloma-specific charity in the world, and serves as a Councilor on the Executive of the American Society of Hematology (ASH).
As a leading multiple myeloma expert, Professor Michael is currently the principal investigator of several clinical trials focussing on the incorporation of immunotherapies into the current treatment algorithm. He personally contributed towards the development of Isatuximab (a CD38 monoclonal antibody, FDA-approved in May 2020 and now sold under the brand name Sarclisa by Sanofi) from its infancy. His other clinical research interests also include pharmaco-economics, communication skills and media relations, with over 100 peer-reviewed articles in these fields.